explore -WSS

explore

author：knowledge 2025-09-30 17:59:41 - browse：9815

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Ibogaine psychedelic therapy for opioid addiction unlikely, official says

WSS

Trump used to be more articulate. What could explain the change?

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Many breast cancer patients receive more radiation than needed

'Patient friction coefficient' can gauge a clinical trial's patient burden

Adam's Take: Intra

Asbestos ban is immediate, but health effects will linger for decades

hotspot

explore

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Texas board proposes rules on abortion law emergency exemption

The high cost of giving birth even with insurance

Doctors push to include dialysis machines in emergency stockpile

Alkermes shareholders re

Mirador, a new biotech startup, launches with $400 million

Alkermes shareholders re

Feed a cold, starve a fever? Here’s what science says

ChatGPT in medicine: STAT answers readers' burning questions

With Wegovy coverage, Medicare patients may face high costs

hotspot

Pfizer, Moderna say biotech, pharma drug development is a sprint

With heat waves through August, officials warn of health risks

With Wegovy coverage, Medicare patients may face high costs

Chinese researcher claims birth of first gene

6 surprising facts about sugar

What Kate Middleton's cancer revelation might teach the world

hotspot

leisure time

focus

Wikipedia